Wall Street brokerages expect Tilray Inc (NASDAQ:TLRY – Get Rating) to post $157.00 million in sales for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Tilray’s earnings, with the highest sales estimate coming in at $165.68 million and the lowest estimate coming in at $150.60 million. Tilray reported sales of $142.24 million in the same quarter last year, which indicates a positive year-over-year growth rate of 10.4%. The company is scheduled to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Tilray will report full-year sales of $643.52 million for the current financial year, with estimates ranging from $625.70 million to $704.19 million. For the next fiscal year, analysts expect that the business will post sales of $722.81 million, with estimates ranging from $658.80 million to $860.69 million. Zacks’ sales averages are an average based on a survey of research firms that follow Tilray.
Tilray (NASDAQ:TLRY – Get Rating) last posted its earnings results on Wednesday, April 6th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.12. The company had revenue of $151.90 million during the quarter, compared to the consensus estimate of $156.64 million. Tilray had a net margin of 6.80% and a negative return on equity of 0.78%. The firm’s quarterly revenue was up 22.6% compared to the same quarter last year.
A number of large investors have recently added to or reduced their stakes in the stock. Concord Wealth Partners acquired a new position in shares of Tilray in the 4th quarter valued at $30,000. Confluence Wealth Services Inc. acquired a new position in shares of Tilray in the 4th quarter valued at $30,000. Dupont Capital Management Corp acquired a new position in shares of Tilray in the 4th quarter valued at $34,000. Farmers & Merchants Trust Co of Chambersburg PA raised its stake in shares of Tilray by 320.0% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 5,250 shares of the company’s stock valued at $41,000 after buying an additional 4,000 shares in the last quarter. Finally, Prospera Financial Services Inc acquired a new position in shares of Tilray in the 1st quarter valued at $54,000. Hedge funds and other institutional investors own 13.84% of the company’s stock.
TLRY stock opened at $3.96 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 2.46 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 20.84 and a beta of 2.54. Tilray has a 12 month low of $3.89 and a 12 month high of $23.04. The firm has a 50 day moving average of $5.40 and a two-hundred day moving average of $6.45.
Tilray Company Profile (Get Rating)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
- Get a free copy of the StockNews.com research report on Tilray (TLRY)
- CrowdStrike earnings and revenue beat forecasts, stock falls
- Ryder System, Inc: The Most Interesting Play In Logistics
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
- First Solar Stock is Ready to Shine
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.